SLSBio(Specialty Lab Solution Bio)에스엘에스바이오
246250 · KOSDAQ · ₩246250 · 에스엘에스바이오
₩1,969 ₩0 (0.00%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩4B | ₩8.4B | ₩9B | ₩11B | ₩8.2B |
| Cost of sales | ₩5.9B | ₩6.1B | ₩5.9B | ₩6.5B | ₩6.1B |
| Gross profit | −₩1.9B | ₩2.3B | ₩3.1B | ₩4.2B | ₩2.2B |
| Operating income | −₩4.1B | ₩288M | ₩1B | ₩2.4B | ₩426M |
| Net income | −₩4.9B | ₩336M | ₩1.4B | ₩2.8B | ₩58M |
| Net income to shareholders | −₩4.9B | ₩336M | ₩1.4B | ₩2.8B | ₩58M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩11B | ₩16B | ₩18B | ₩12B | ₩11B |
| Current assets | ₩4.5B | ₩9.8B | ₩12B | ₩6.1B | ₩3.8B |
| Cash and equivalents | ₩278M | ₩1.1B | ₩1.8B | ₩1.5B | ₩1.4B |
| Total liabilities | ₩3.6B | ₩3.8B | ₩4.4B | ₩5B | ₩6.8B |
| Current liabilities | ₩1.6B | ₩1.5B | ₩1.7B | ₩2B | ₩3.4B |
| Borrowings | — | ₩0 | ₩0 | ₩0 | ₩1.8B |
| Total equity | ₩7.6B | ₩13B | ₩13B | ₩6.7B | ₩3.7B |
| Shareholders' equity | ₩7.6B | ₩13B | ₩13B | ₩6.7B | ₩3.7B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩2.2B | ₩1.7B | ₩3.4B | ₩4B | ₩2.3B |
| Capital spending | ₩1.5B | ₩1.5B | ₩1.3B | ₩719M | ₩778M |
| Free cash flow | −₩3.7B | ₩270M | ₩2.2B | ₩3.3B | ₩1.5B |
| Dividends paid | — | ₩384M | — | — | — |
Consolidated where available. Amounts in won.
Also known as: SLSBio(Specialty Lab Solution Bio) / 에스엘에스바이오 / 246250 / KRX:246250
Source: KRX statistical information